Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04729946 · ClinicalTrials.gov registry record · NA
Clinical and Urgent Colonoscopy Outcomes Using the Pure-Vu® Cleansing System
A NA study, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT04729946: Clinical Trial NA study, sponsored by The Cleveland Clinic.
NCT04729946 is a NA study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04729946, a NA study, was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The Pure-Vu® System can be effectively used as a cleansing device in patients admitted with acute LGIB to the intensive care unit and the regular nurse floor (RNF) bypassing the need to administer an oral bowel preparation for adequate visualization and hence decreasing time to colonoscopy and improving diagnostic and therapeutic yield.
Primary Outcome
The proportion of participants who achieve an adequate bowel preparation to identify bleeding lesions
Interventions
- DEVICE Pure-Vu Cleansing Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2022-04-06 |
| Phase | NA |
Why NCT04729946 stopped before completion
NCT04729946 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Pure-Vu Cleansing Device is the first listed.
NCT04729946 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04729946 about?
NCT04729946 is a clinical study titled "Clinical and Urgent Colonoscopy Outcomes Using the Pure-Vu® Cleansing System". The Pure-Vu® System can be effectively used as a cleansing device in patients admitted with acute LGIB to the intensive care unit and the regular nurse floor (RNF) bypassing the need to administer an oral bowel preparation for adequate visualization and hence decreasing time to colonoscopy and impro...
What is the current status of trial NCT04729946?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2021-03-03. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT04729946?
The interventions under investigation include: Pure-Vu Cleansing Device (DEVICE).
Who is sponsoring clinical trial NCT04729946?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04729946's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI